Teriflunomide reduces relapses with sequelae and relapses leading to hospitalizations: results from the TOWER study

Randomized Trial of Oral Teriflunomide for Relapsing Multiple Sclerosis

Paul O’Connor, Jerry S. Wolinsky, Christian Confavreux et al. · New England Journal of Medicine · 2011 · 965 citations · Full text

Oral teriflunomide for patients with relapsing multiple sclerosis (TOWER): a randomised, double-blind, placebo-controlled, phase 3 trial

Christian Confavreux, Paul O’Connor, Mark Freedman et al. · The Lancet Neurology · 2014 · 566 citations

Oral Teriflunomide, Neurological Disorder, Medicine +6

Long-term follow-up of a phase 2 study of oral teriflunomide in relapsing multiple sclerosis: safety and efficacy results up to 8.5 years

Christian Confavreux, David K. Li, Mark S. Freedman et al. · Multiple Sclerosis Journal · 2012 · 140 citations · Full text

Cost of managing an episode of relapse in multiple sclerosis in the United States

Judith A. O’Brien, Alexandra Ward, Amanda R. Patrick · BMC Health Services Research · 2003 · 107 citations · Full text

Burden of a Multiple Sclerosis Relapse

MerriKay Oleen-Burkey, Jane Castelli‐Haley, Maureen J. Lage et al. · Patient · 2012 · 79 citations

Multiple Sclerosis Relapse, Disease Progression, Neurological Disorder +5